Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCerillion Regulatory News (CER)

Share Price Information for Cerillion (CER)

Share Price is delayed by 15 minutes
Get Live Data
1,245.00    0.00 (0.00%)
Bid:
1,230.00
Ask:
1,260.00
Spread: 30.00 (2.439%)
Market Cap: £367.78m
CER Live PriceLast checked at - London Stock Exchange

Intraday Cerillion Share Chart

Further concentrate purchase

1 Oct 2007 07:02

Celtic Resources Holdings PLC01 October 2007 1 October 2007 Celtic Resources Holdings Plc ("Celtic" or the "Company") Celtic enters into agreement to purchase concentrates Celtic is pleased to announce that it has entered into an agreement with asubsidiary of European Goldfields Limited, Hellas Gold S.A. ("Hellas Gold"), forthe purchase of 50,000 tonnes of concentrates containing approximately 30,000 ozof gold. As announced on 22 September 2006, the Company acquired 9,000 tonnes ofconcentrate containing approximately 6,000 oz of gold, to be processed on atrial basis, by Celtic at its Suzdal BIOX(R) plant in Kazakhstan. The Companyalso announced that, if the initial shipments proved successful, it intended topurchase up to an additional 120,000 tonnes of concentrates from Hellas Gold.The Company has been very satisfied by the results of the trial and is thereforeannouncing an agreement to purchase a further 50,000 tonnes of concentrates,with shipments expected to be completed by the end of September 2009. The Company operates the only BIOX(R) plant in the FSU for the treatment ofrefractory sulphide ores and in addition to treating ore produced at its Suzdalmine, it will be utilising available BIOX(R) capacity to produce more gold. Suzdal has produced over 28,599 oz of gold in the last three months, whichincludes 11,780 oz produced in September, at an average sale price of US$718 peroz. Kevin Foo, Managing Director of Celtic, said, "We have been delighted with theresults of our initial trial to process third party concentrates at our SuzdalBIOX(R) plant. This agreement is a significant step forward in our strategy tocapitalise on our technology advantages at Suzdal and we are also looking atother third party concentrate opportunities within Kazakhstan and Russia, asmany refractory gold ores remain unexploited." Contact information: Kevin Foo / Jonathan Scott-BarrettCeltic Resources Holdings PlcTel: + 44 (0)20 7921 8800Investors@celtic resources.com Leesa Peters / Jane StaceyConduit PRTel: +44 (0)20 7429 6606 / (0)792 292 3306leesa@conduitpr.com Anthony CardewCardew GroupTel: +44 (0)20 7930 0777anthony.cardew@cardewgroup.com Strand Partners LimitedSimon RaggettStuart FaulknerTel: +44 (0)20 7409 3494 About the Suzdal BIOX(R) plant: Celtic has successfully developed the first BIOX(R) plant for treatment ofrefractory sulphide ores in the FSU at its Suzdal mine in Kazakhstan. The plantuses a sulphide oxidation process for recovering gold from refractory ores orconcentrates. The process utilises a mixed population of naturally occurringbacteria, that are present in all sulphide ores, to break down the sulphidemineral matrix, thereby liberating the occluded gold for subsequent cyanidation. The BIOX(R) process acts as an alternative to conventional processes of roastingand pressure oxidation and offers advantages of reduced capital cost, simplicityof operations, robustness and very low environmental impact. Any person who is the holder of 1 per cent. or more of any class of shares inCeltic may be required to make disclosures pursuant to Rule 8.3 of the IrishTakeover Panel Act, 1997, Takeover Rules 2001 to 2006. The Directors of Celtic accept responsibility for the information contained inthis announcement and to the best of their knowledge and belief (having takenall reasonable care to ensure that such is the case), the information containedin this announcement is in accordance with the facts and, where appropriate,does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st May 202112:26 pmRNSDirector/PDMR Shareholding
17th May 20214:33 pmRNSHolding(s) in Company
17th May 20217:00 amRNSInterim Results
19th Apr 20217:00 amRNSHalf Year Trading Update
29th Mar 20217:00 amRNSLargest Ever Contract Win
17th Mar 20215:47 pmRNSShare Purchase for Long-Term Incentive Plan
12th Mar 20215:43 pmRNSDirector/PDMR Shareholding
11th Mar 20217:00 amRNSMajor Channel Partner Yields First Contract
11th Feb 20215:14 pmRNSDirector/PDMR Shareholding
9th Feb 20217:00 amRNSPDMR Share Transfer
5th Feb 20219:31 amRNSResult of AGM
4th Feb 20213:00 pmRNSHolding(s) in Company
4th Feb 202112:09 pmRNSDirector/PDMR Shareholding
2nd Feb 20214:13 pmRNSDirector/PDMR shareholding
30th Dec 20207:00 amRNSHolding(s) in Company
18th Dec 20206:07 pmRNSHolding(s) in Company
18th Dec 20201:17 pmRNSHolding(s) in Company
26th Nov 20208:53 amRNSHolding(s) in Company
24th Nov 20204:41 pmRNSSecond Price Monitoring Extn
24th Nov 20204:37 pmRNSHolding(s) in Company
24th Nov 20204:36 pmRNSPrice Monitoring Extension
23rd Nov 20207:00 amRNSFinal Results
18th Nov 20207:00 amRNSNew Three Year Managed Services Contract
6th Nov 20204:44 pmRNSHolding(s) in Company
6th Nov 20204:25 pmRNSHolding(s) in Company
6th Nov 20204:21 pmRNSHolding(s) in Company
27th Oct 20201:55 pmRNSHolding(s) in Company
20th Oct 202011:17 amRNSExercise of Options and Share Transfer
15th Oct 20207:00 amRNSTrading Update
16th Sep 20203:18 pmRNSHolding(s) in Company
15th Sep 20209:05 amRNSSecond Price Monitoring Extn
15th Sep 20209:00 amRNSPrice Monitoring Extension
15th Sep 20207:00 amRNSLargest Ever Contract Win
3rd Sep 202011:11 amRNSShare purchase for Long Term Incentive Plan
30th Jul 20203:08 pmRNSHolding(s) in Company
23rd Jul 20204:14 pmRNSHolding(s) in Company
1st Jul 20207:00 amRNSMajor Implementation Completed Remotely
10th Jun 20207:00 amRNSHolding(s) in Company
8th Jun 20205:43 pmRNSResult of Director Placing
8th Jun 20204:35 pmRNSProposed Director Placing
1st Jun 20207:00 amRNSDirector Retirement
11th May 20207:00 amRNSInterim Results
20th Apr 20207:00 amRNSHalf Year Trading Update
16th Mar 20207:00 amRNSChange of Adviser
10th Mar 20207:00 amRNSExercise of Options and Total Voting Rights
3rd Mar 20207:00 amRNSExercise of Options and Director/PDMR Shareholding
27th Feb 20204:45 pmRNSShare Purchase for Employee Share Option Scheme
26th Feb 20207:00 amRNSDirector/PDMR Shareholding
20th Feb 202011:52 amRNSHolding(s) in Company
13th Feb 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.